Prophylactic Phasix™ Mesh for Incisional Hernia Prevention in IBD Surgery: A Prospective Multicenter Study (ProPhIS)

November 17, 2026 updated by: Matteo Rottoli, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Assessing the Incidence of Incisional Hernia Rates in Inflammatory Bowel Disease Patients Undergoing Open or Minimally Invasive Abdominal Surgery With Use of Prophylactic Phasix™ Mesh Reinforcement: A Multicenter, Single-Arm, Two Strata Prospective Study.

The goal of this clinical trial is to evaluate the incidence of incisional hernia, detected by ultrasound imaging, two years after surgery in patients with Inflammatory Bowel Disease (IBD) undergoing either open or minimally invasive abdominal surgery with the use of prophylactic Phasix™ Mesh reinforcement. The study focuses on consecutive adult patients aged 18 years or older with a confirmed histological diagnosis of Crohn's disease or Ulcerative Colitis who are scheduled for elective abdominal surgery, specifically minimally invasive surgery requiring a periumbilical incision for specimen extraction or open abdominal surgery via a midline incision for patients undergoing their second or subsequent abdominal operation for IBD. The main questions it aims to answer are: what is the rate of 24-month incisional hernia as diagnosed by ultrasound imaging in the prospective study population, and how do secondary outcomes such as postoperative pain, quality of life, surgical site occurrences, and 90-day complication rates compare across these surgical strata? If there is a comparison group: Researchers will compare participants who received open surgery to those who received minimally invasive surgery to see if there are significant differences in the 24-month incisional hernia rates, complication profiles, and recovery metrics. Participants will undergo their planned abdominal surgery according to standard institutional care pathways, during which the study device-the Phasix™ Mesh-will be positioned to reinforce either the periumbilical extraction site in minimally invasive procedures or the midline incision in open surgeries using a standardized onlay technique. Following surgery, participants will be asked to complete a series of main tasks and evaluations, which include providing daily self-reported pain ratings on a Visual Analog Scale during hospitalization, attending scheduled follow-up visits at 30 days, 6 months, 12 months, and 24 months post-surgery, undergoing clinical evaluations and wound inspections with standardized photographic documentation at each visit, completing validated questionnaires including the Short-Form Health Survey-36, Ventral Hernia Pain Questionnaire, and Carolinas Comfort Scale at specified postoperative time points, and undergoing delegated ultrasound imaging of the entire length of the incision in both supine resting and dynamic states during the 12-month and 24-month follow-up visits to detect any occult or overt fascial defects or herniation.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult patients aged ≥ 18 years at the time of screening.

  • Confirmed (histologically proven) diagnosis of Crohn's disease or Ulcerative Colitis.

  • Scheduled to undergo abdominal surgery, specifically:

    • Minimally invasive surgery (laparoscopic or robotic) requiring a periumbilicaln incision for specimen extraction.
    • Open abdominal surgery (laparotomy) via a midline incision, for patients undergoing their second or subsequent abdominal operation for IBD.
  • Willingness and ability to provide informed consent.

  • Willingness and ability to comply with follow-up requirements, including ultrasound examinations.

Exclusion Criteria:

  • Emergency surgery (e.g., for perforation with gross contamination, hemodynamic instability requiring immediate life-saving surgery without time for prophylactic mesh consideration).
  • Presence of an existing incisional hernia at the planned incision site.
  • Known allergy or hypersensitivity to any components of Phasix™ Mesh. In particular, known allergy to tetracycline hydrochloride or kanamycin sulfate.
  • Current gross abdominal sepsis or infection that, in the surgeon's judgment, would contraindicate mesh placement.
  • Life expectancy less than two years.
  • Pregnant or breastfeeding women.
  • Participation in another interventional trial that might confound the study results.
  • Previous mesh placement at the index incision site (for open surgery patients)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MIS with Phasix Mesh Reinforcement

Patients with Inflammatory Bowel Disease undergoing elective minimally invasive (laparoscopic or robotic) abdominal surgery who receive prophylactic Phasix Mesh reinforcement of the periumbilical specimen extraction site using a standardized technique.

A fully resorbable monofilament scaffold (Phasix Mesh) placed during elective abdominal surgery to reinforce either the periumbilical specimen extraction site in minimally invasive surgery or the midline incision in open surgery, using a standardized onlay technique.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the rate of 24-month incisional hernia
Time Frame: baseline

diagnosed by ultrasound imaging

baseline

Secondary Outcome Measures

Outcome Measure
Time Frame
rate of 12-month incisional hernia
Time Frame: baseline
baseline
median value of the participants-reported pain
Time Frame: study visits after surgey
study visits after surgey
The median value of the Ventral Hernia Pain Questionnaire (VHPQ)
Time Frame: after surgery
after surgery
The median value of the Short-Form Health Survey-36 (SF-36)
Time Frame: after surgery
after surgery
The median value of the Carolinas Comfort Scale (CCS)
Time Frame: after surgery
after surgery
The median difference in the 24-month VAS scores
Time Frame: 24 month after surgery
24 month after surgery
The rate of 90-day postoperative complications classified according to the Clavien-Dindo scale
Time Frame: 90 after surgery
90 after surgery
The rate of 90-day reoperations
Time Frame: 90 after surgery
90 after surgery
The rate of 24-month incisional hernia between the participants who received open surgery and those who received MIS.
Time Frame: 24 months after surgery
24 months after surgery
The median difference in the 24-month VHPQ scores
Time Frame: 24 months after surgery
24 months after surgery
The median difference in the 24-month SF-36 scores
Time Frame: 24 months after surgery
24 months after surgery
The median difference in the 24-month CCS scores
Time Frame: 24 months after surgery
24 months after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 31, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 31, 2029

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • ProPhIS
  • CyberGrant 103751599 (Other Grant/Funding Number: Becton Dickinson Holdings Pte Ltd)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe